Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors

NCT02882659 is registered in ClinicalTrials.gov with FullHope Biomedical Co., Ltd. as lead sponsor.

NCT NCT02882659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02882659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Lead sponsor
FullHope Biomedical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2014
Completion date
December 31, 2017
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, hepatocellular carcinoma, neoplasm metastasis